ADME 독성 시험 시장 규모, 점유율, 동향 및 예측 : 기술, 제품 유형, 방법, 용도, 지역별(2026-2034년)

The global ADME toxicology testing market size reached USD 11.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 30.7 Billion by 2034, exhibiting a growth rate CAGR of 11.20% during 2026-2034. North America exhibits a clear dominance in the ADME toxicology testing market with a 41.5% share of the market. This region drives the ADME toxicology testing market through advanced healthcare infrastructure, high R&D investments, widespread adoption of predictive testing technologies, and regulatory emphasis on drug safety and efficacy standards.

The growing importance of reducing post-discovery drug phase failures is a key driver for the ADME toxicology testing market. Pharmaceutical and biotechnology companies are increasingly focused on innovating modern ADME toxicology methods, which are essential for early assessment of absorption, distribution, metabolism, and excretion profiles, as well as toxicity risks. This ongoing advancement is contributing to the continued growth of the drug development sector. For example, in 2024, Beckman Coulter Life Sciences took the revolutionary step of bringing in the Cydem VT Automated Clone Screening System, a process that has the capacity of automatically developing a cell line with 90% fewer steps, thus making biological drug discovery a completely passive process. This approach minimizes costly setbacks during clinical trials, enhances drug safety profiles, and accelerates time-to-market for new therapies. Regulatory authorities' growing demand for stringent preclinical testing standards further bolsters adoption, positioning ADME toxicology testing as a critical component in modern drug discovery and development pipelines, driving significant market growth.

The United States is demonstrating magnifying growth in the ADME toxicology testing market due to its innovative pharmaceutical and biotechnology sectors, significant drug development research, and strict regulatory measures for the safety of drugs. For example, in 2024, Insilico Medicine presented five preclinical cancer drug programs at the 2024 AACR Annual Meeting. The company's AI platform developed small-molecule inhibitors, including ISM6331 targeting TEAD and ISM8001, a dual FGFR2/FGFR3 inhibitor, which showed 80-120% tumor growth inhibition in preclinical models. Insilico also secured partnerships, including an $80M deal with Exelixis and a $500M agreement with Menarini for additional cancer treatments. Additionally, the integration of advanced technologies like high-throughput screening and in silico modeling, alongside growing collaborations between academia and industry, fuels the demand for precise toxicology testing solutions, reinforcing the U.S.'s leadership in ADME testing innovation.

ADME TOXICOLOGY TESTING MARKET TRENDS:

Increasing Prevalence of Chronic Diseases

One of the principal factors driving growth in the ADME toxicology testing sector is the rise of chronic diseases worldwide. Serious ailments such as cancer, diabetes, and cardiovascular diseases need the need for lots of new medicines to be researched and developed. The World Health Organization says noncommunicable diseases (NCDs) cause 41 million deaths each year, making up 74% of all deaths globally. Of these, 17 million people die before age 70, with 86% of these early deaths happening in low- and middle-income countries. ADME toxicity testing stands out as the most important method of ensuring the safety and efficacy of the pharmaceuticals concerned. In the midst of the continued health problems and conditions caused by some diseases all over the world, there is a big need for the reduction of side effects of drugs as well as the safety of patients through drug testing. ADME toxicology testing provides crucial information on how drugs are absorbed, distributed, metabolized, and eliminated by the body. This process is essential for developing safe and effective treatments for chronic conditions. Thus, this continued demand for new pharmaceutical solutions to chronic conditions drives the growth of the market.

Technological Advancements

Technological advancements are rapidly increasing the ADME toxicology testing market. The modern testing processes like in vitro and in silico models over traditional methods of in vivo are increasingly adopted with a lot more accuracy, efficiency, and cost-effectiveness in the testing options. For instance, in 2024, Capstan Therapeutics secured $175 million to advance its in vivo cell therapy platform, which aims to reprogram cells within the body and move its lead candidate into clinical trials. This type of new approach is animal test-dependent to a reduced degree, complies with ethical considerations, and shows quicker results. Technological advances have also facilitated the creation of high-throughput screening methods, where it is possible to test multiple drug compounds at the same time, greatly speeding up the drug development process. In addition, the progress in computational biology and bioinformatics is improving the predictability of ADME toxicology tests, thus increasing their reliability and efficiency.

Increasing Regulatory Compliance

The strict regulatory measures made by authorities like the FDA and EMA for drug approval are another significant driver for the ADME Toxicology Testing market. These regulatory agencies require safety studies of novel drug substances to be conducted before the latter can be approved for human use. For example, in April 2024, the FDA approved Selarsdi 45 mg/0.5 ml and 90 mg/ml injections for subcutaneous administration to treat moderate to severe plaque psoriasis and active psoriatic arthritis in patients aged 6 and older. Thus, ADME toxicology testing is an important component since it provides necessary information on potential toxic effects on human health. In new compound development, new complexity emerges where people, in general, are much more sophisticated in drug-induced toxicities, and this brings stronger regulatory requirements.

Expanding Pharmaceutical Industry

A key driver of the ADME market is the substantial rise in research and development spending within the pharmaceutical industry. As companies allocate more resources to developing novel drugs, the demand for thorough ADME toxicology testing grows, ensuring both the safety and effectiveness of these medications. This testing is critical in identifying potential toxic effects and metabolic pathways early in the drug development process, thereby reducing the risk of late-stage failures. Increasing overall sales of pharmaceuticals across the globe coupled with rising demand for innovative drugs is further augmenting research and development. According to a recent analysis from one of the leading pharma consulting firms, the overall spending and global demand for medicines will rise over the next five years to around USD 1.9 Trillion by 2027. Additionally, the increasing complexity of emerging pharmaceutical compounds has led to a greater dependence on advanced ADME toxicology studies to comprehend how these drugs interact within the body. This demand is further amplified by stringent regulatory standards, which require comprehensive toxicology testing prior to drug approval, fueling growth in this sector.

ADME TOXICOLOGY TESTING INDUSTRY SEGMENTATION:

Analysis by Technology:

• Cell Culture
• High Throughput Screening
• Molecular Imaging
• OMICS Technology
• Others

Cell culture leads the market with around 43.6% of the market share in 2025. This recognition is associated with the ability to mimic the behavior of living organisms, producing accurate and reliable data for drug absorption, distribution, metabolism, and excretion research. The application of sophisticated methods, like 3D cell cultures, and organ-on-a-chip models, has significantly increased the significance of cell culture in preclinical studies. Through the ability to decrease the use of animals, testing and to enhance predictive capability, cell culture remains a leader in the development of drugs.

Analysis by Product Type:

• Instruments
• Software Solutions
• Assay Systems
• Reagents
• Others

This leadership of software solutions is to a great extent due to their effectiveness in making data analysis more efficient and decision-making more effective in several different industries. Their usage is the most in the fields of healthcare, finance, and logistics for operations such as predictive modeling, automation, and operational optimization. Advanced software, including AI-driven platforms and cloud-based tools, enables organizations to process large datasets accurately and efficiently. The demand for software solutions is further fueled by the need for scalability, cost reduction, and enhanced productivity across diverse applications.

Analysis by Method:

• In-Vivo
• In-Vitro
• In-Silica
• Others

In-vivo leads the market as methods play a crucial role in making toxicology studies more capable and more accurate by giving more sophisticated methods of data analysis, modeling, and simulation. Through the alignment of software and cloud-based AI tools, reliable results of drug absorption, distribution, metabolism, and excretion are obtained, enabling faster and more cost-effective preclinical evaluations. Their integration reduces the reliance on manual processes and animal testing, streamlining drug development pipelines. The growing emphasis on precision and regulatory compliance further drives their adoption.

Analysis by Application:

• Systemic Toxicity
• Renal Toxicity
• Hepatotoxicity
• Neurotoxicity
• Others

Systematic toxicity leads the market with around 53.8% of the market share in 2025. This testing focuses on assessing the adverse effects of drug candidates on various organ systems over time, ensuring comprehensive safety evaluations. It plays a critical role in identifying potential long-term and cumulative toxicities that could compromise drug efficacy or patient health. Regulatory bodies emphasize systematic toxicity studies to meet stringent safety standards. Advances in predictive modeling and integration with in-vivo and in-vitro techniques further enhance its precision, solidifying its market leadership.

Regional Analysis:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 41.5%. This leadership is driven by the region's advanced healthcare infrastructure, significant investment in pharmaceutical and biotechnology research, and a strong focus on regulatory compliance. The widespread adoption of advanced technologies, such as high-throughput screening and in-silico modeling, enhances the precision and efficiency of toxicology testing. Additionally, the growing prevalence of chronic diseases and demand for innovative drug therapies further fuel market growth. North America remains at the forefront of innovations and industry advancements in ADME toxicology testing.

Key Regional Takeaways:

UNITED STATES ADME TOXICOLOGY TESTING MARKET ANALYSIS

The US accounts for 84.8% share of the market in North America. The strong pharmaceutical and biotechnology industries in the US are driving the market for ADME toxicity testing. To guarantee drug safety and efficacy, dependable ADME (Absorption, Distribution, Metabolism, and Excretion) testing is essential due to significant investment in drug development and strict regulatory standards enforced by organizations such as the FDA. More than USD 100 Billion was spent on pharmaceutical R&D in the United States in 2022, which greatly increased the need for sophisticated testing techniques. Although this is a rather expanding market, around less than 30% of the newly discovered drugs successfully transition to Phase III clinical trials after passing through Phase II. Examples of technology revolutions that are saving costs and time in the testing procedures are high-throughput screening, as well as in silico testing. More dependence on artificial intelligence by humans in the ADME investigation satisfies the demand for techniques of non-animal testing in which better predictive toxicology becomes feasible. Another area that the U.S. is experiencing is an upsurge in outsourcing ADME services to dedicated CROs for greater efficiency and reduced cost-effectiveness. The development of chronic diseases and customized therapies also generates a high need for precise toxicological tests. For example, accurate profiles for ADME are a significant requirement for targeted anticancer therapy. Intersectoral agreements of the government with the private sectors and the academia-like NIH's NCATS program-is supporting the market to grow as well. The U.S. industry is likely to lead with a healthy compound annual growth rate (CAGR) propelled by ongoing innovation and regulatory compliance.

EUROPE ADME TOXICOLOGY TESTING MARKET ANALYSIS

Due to strict regulatory frameworks, including the European Medicines Agency's (EMA) recommendations for medication safety assessment, Europe is a major player in the ADME toxicity testing market. Key contributions include nations like Germany, the United Kingdom, and France, which profit from robust pharmaceutical industries and significant R&D expenditures. the pharmaceutical business made a substantial contribution to the EU economy in 2022, contributing Euro 311 Billion (USD 326 Billion). However, according to the most recent data from the European Federation of Pharmaceutical Industries and Associations (EFPIA), Europe's R&D investment growth has averaged 4.4% per year since 2010. The region's focus on minimizing animal testing is consistent with developments in substitute techniques like as computational toxicology and organ-on-a-chip technology. The need for thorough toxicological testing is further fuelled by programs like REACH (Registration, Evaluation, Authorisation, and Restriction of Chemicals), particularly for environmental safety. ADME testing is required due to the rising incidence of lifestyle-related diseases such as diabetes and cardiovascular problems, which drive medication development efforts. Furthermore, the necessity for accurate ADME profiling is increased by Europe's emphasis on biologics and personalised treatment. With a growing ecosystem of CROs and government support for innovative research, the market is projected to grow steadily in the coming years.

ASIA PACIFIC ADME TOXICOLOGY TESTING MARKET ANALYSIS

The market for ADME toxicity testing is growing quickly in Asia-Pacific due to the expansion of pharmaceutical manufacturing in nations like China and India. Global pharmaceutical companies are drawn to the region's affordable drug development capabilities, which increases demand for ADME testing services. As Asia accounts for a growing share of their global revenues and, more significantly, most of their growth, many multinational pharmaceutical firms are witnessing this personally. As per several industrial reports, about 20% to 30% of their 2021 sales came from Asia, with China accounting for about half of that total. More than 220 novel treatments have been approved since China joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and the period between China's approval and the first approval has been reduced. Government programs like China's emphasis on developing breakthrough medicines and India's "Pharma Vision 2020" also help the market grow. Adoption of ADME testing is fuelled by the incidence of chronic diseases and rising healthcare costs, which increase the demand for safer medications. To satisfy the region's expanding needs, technological innovations including automated testing and high-throughput are being adopted. Asia-Pacific is expected to grow at a faster rate than the rest of the world, making it a major hub for ADME toxicity testing services.

LATIN AMERICA ADME TOXICOLOGY TESTING MARKET ANALYSIS

The market for ADME toxicity testing is expanding in Latin America owing to increased pharmaceutical research and development as well as growing healthcare consciousness. Due in large part to expanding domestic drug production and government funding for research projects, Brazil, Mexico, and Argentina are major producers. Due to the region's emphasis on generic and biosimilar medications, significant ADME testing is required for regulatory clearance. Testing skills are further improved by collaborations between domestic and international pharmaceutical businesses. The need for safe and efficient drugs is also fuelled by the increase in chronic illnesses and easier access to healthcare systems. With its growing pharmaceutical infrastructure and affordable services, Latin America offers a profitable market. Moreover, in Latin America and the Caribbean, chronic conditions like heart disease, cancer, and diabetes are leading contributors to death and disability worldwide. Diabetes affects one in ten adults, while nearly 80% of fatalities are linked to these long-term illnesses, as per an industrial report.

MIDDLE EAST AND AFRICA ADME TOXICOLOGY TESTING MARKET ANALYSIS

The MENA region is experiencing a troubling increase in chronic conditions. Heart disease, diabetes, cancer, and respiratory disorders represent a substantial share of the region's overall health challenges. According to the World Health Organization (WHO), NCDs account for approximately 70% of deaths in the region. Urbanization, sedentary lifestyles, unhealthy diets, tobacco use, and obesity contribute to the high prevalence of these diseases. The increased pharmaceutical investments in nations like South Africa and the United Arab Emirates are driving growth in the Middle East and Africa (MEA) ADME toxicity testing market. The need for ADME services is increased by growing healthcare infrastructure and government funding for research and development. The necessity for accurate toxicological testing is fuelled by the region's rising clinical trials and high prevalence of infectious diseases. Partnerships with international pharmaceutical companies also improve local testing capacities. The MEA market is anticipated to increase steadily as knowledge of cutting-edge ADME technology rises, albeit more slowly than in other areas.

COMPETITIVE LANDSCAPE:

Market leaders are pursuing strategic actions to strengthen their market position. These efforts involve mergers and acquisitions to broaden their range of services, partnerships with pharmaceutical firms for early-stage toxicity evaluations, and the creation of advanced technologies for ADME testing. Additionally, market leaders are focusing on geographic expansion, especially in high-growth regions like Asia-Pacific and Latin America, to tap into emerging markets. For instance, in 2024, BioIVT showcased its new Ki67 tissue staining service for ADC development at Biomarkers U.S. 2024 and SITC 2024, emphasizing its commitment to advancing drug and diagnostic research.

The report provides a comprehensive analysis of the competitive landscape in the ADME toxicology testing market with detailed profiles of all major companies, including:

• Agilent Technologies Inc.
• Beckman Coulter Inc. (Danaher Corporation)
• Bioivt LLC
• Bio-Rad Laboratories Inc.
• Charles River Laboratories International Inc.
• Cyprotex Plc (Evotec AG)
• Molecular Discovery Ltd.
• Perkinelmer Inc.
• Promega Corporation
• Thermo Fisher Scientific, Inc.

Key Questions Answered in This Report

• 1.How big is the ADME toxicology testing market?
• 2.What is the future outlook of ADME toxicology testing market?
• 3.What are the key factors driving the ADME toxicology testing market?
• 4.Which region accounts for the largest ADME toxicology testing market share?
• 5.Which are the leading companies in the global ADME toxicology testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global ADME Toxicology Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 Cell Culture
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 High Throughput Screening
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Molecular Imaging
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 OMICS Technology
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Product Type

• 7.1 Instruments
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Software Solutions
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Assay Systems
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Reagents
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Method

• 8.1 In-Vivo
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 In-Vitro
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 In-Silica
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Application

• 9.1 Systemic Toxicity
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Renal Toxicity
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Hepatotoxicity
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Neurotoxicity
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agilent Technologies Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Beckman Coulter Inc. (Danaher Corporation)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 SWOT Analysis
  • 15.3.3 Bioivt LLC
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Bio-Rad Laboratories Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Charles River Laboratories International Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Cyprotex Plc (Evotec AG)
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Molecular Discovery Ltd.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Perkinelmer Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Promega Corporation
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Thermo Fisher Scientific Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis